RxDoctor Payments Data

Sekhar Gollapalli, MD

Internal Medicine · Hauppauge, NYNPI 1619932167

Payments from drug & device makers

$417in general payments, 2019–2025

Across 14 payments — averaging $29.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$149
  • AstraZeneca$125
  • Novo Nordisk$90
  • Johnson & Johnson$52

What the payments were for

  • Food & beverage$417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer11$149
AstraZeneca1$125
Novo Nordisk1$90
Johnson & Johnson1$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$397,189
Medicare patients
316
Services billed
3,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$128,642
OzempicSemaglutide35$48,121
MyrbetriqMirabegron72$32,897
FarxigaDapagliflozin Propanediol37$32,634
JardianceEmpagliflozin35$32,037
XareltoRivaroxaban27$28,469
JanuviaSitagliptin Phosphate34$27,530
GemtesaVibegron25$11,947
TradjentaLinagliptin12$10,060
EntrestoSacubitril/Valsartan11$9,759
XanaxAlprazolam11$8,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,183
VerquvoVericiguat13$7,274
CreonLipase/Protease/Amylase12$6,239
Memantine Hcl ErMemantine Hcl37$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$128,642195 claims
Novo NordiskOzempic$90$48,12135 claims
AstraZenecaFarxiga$125$32,63437 claims
Johnson & JohnsonXarelto$52$28,46927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hauppauge

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →